ESTRO 2025 - Abstract Book

S149

Invited Speaker

ESTRO 2025

but potentially synergistic, as radiation-mediated antigen release may enhance immune-mediated tumor regression.

Although large-scale phase III trials dedicated to RCC are underway, a robust body of data from other malignancies supports integrating SBRT with systemic therapies. In non–small cell lung cancer, the addition of immunotherapy to high-dose radiation has extended survival, illustrating how ablative doses can potentiate immune responses. Similarly, in oligometastatic prostate and hepatocellular cancers, local radiotherapy has been shown to prolong progression-free survival when combined with standard systemic regimens. Translation of these insights to RCC hinges on careful patient selection and optimal sequencing. Patients with oligometastatic disease may especially benefit from SBRT, which can target limited progressing lesions while preserving a systemic regimen that is otherwise effective. The timing of SBRT—whether before or after initiating systemic therapy—remains an area of active study, with multiple ongoing trials examining its role in various clinical contexts. In conclusion, the integration of SBRT with targeted agents and immune checkpoint inhibitors represents a promising frontier in kidney cancer management. By combining high-precision local therapy with systemic approaches, clinicians can strive to maximize tumor control, potentially prolong survival, and offer a new paradigm of care for selected RCC patients. Finally, this presentation will delve into the latest evidence, discuss emerging clinical trials, and outline practical strategies for optimizing combined-modality therapy in RCC.

4916

Speaker Abstracts Can an integrated approach improve the balance between local control and QoL? Peter Koelblinger Dermatology and Allergology, Paracelsus Medical University, Salzburg, Austria

Abstract:

An integrated approach to the treatment of non-melanoma skin cancers (NMSC) involves a combination of medical, surgical, and radiotherapeutic strategies tailored to the unique needs of each patient. This approach aims to improve clinical outcomes by enhancing local control of the tumor while minimizing the adverse effects on the patient’s quality of life (QoL). In recent years, the growing emphasis on personalized medicine has prompted a re-evaluation of treatment protocols to achieve a more harmonious balance between disease management and patient well-being. Hence, quality of life (QoL) has become an essential consideration in the treatment of NMSC, given the chronic nature of certain cancer types and the potential for disfigurement following surgical interventions in advanced disease stages. Several studies have focused on assessing QoL outcomes in patients with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and Merkel cell carcinoma (MCC). Recently introduced neoadjuvant treatment strategies— i.e. the combination of systemic checkpoint inhibitor therapy and localized treatment—offer promising outcomes in improving both local control and QoL. Personalized care plans based on tumor characteristics and patient factors can tailor the approach to ensure better results. The multi-disciplinary integration of surgical, radiotherapeutic and immune-oncological treatment modalities may reduce recurrence rates and minimize post-treatment complications, ultimately supporting improved QoL outcomes.